Navigation Links
Researchers closing in on safe treatment for parasitic diseases
Date:7/8/2011

EAST LANSING, Mich. With the help of another $2 million in funding from the Bill & Melinda Gates Foundation, researchers are moving closer to setting up human clinical trials for a reformulated drug that could be the linchpin of treatment efforts against two debilitating tropical diseases.

Charles Mackenzie, a professor of veterinary pathology in Michigan State University's College of Veterinary Medicine, and his colleagues are looking to flubendazole, a drug tested first in the 1980s to treat the filarial disease river blindness (onchocerciasis).

The disease, in which the skin and eyes are infected with parasitic worms, afflicts about 40 million people worldwide, much of its damage in equatorial Africa. River blindness is spread by black flies, and after the parasitic worms die in a person's eye, it can cause blindness and debilitating skin disease.

Another filarial disease, elephantiasis (lymphatic filariasis), is caused by tiny worms in the vascular system and is spread via mosquitoes. It results in severe swelling of the legs, arms and torso, and the physical deformities and disabilities cause tremendous psychological problems and economic hardship to millions of people in most of the tropical regions of the world.

Researchers are focusing treatment efforts on flubendazole, a drug used in the 1980s with good results against adult filarial worms when it was injected in animals and humans. However, the injections caused severe local reactions and the drug formulation at that time gradually lost effectiveness. Mackenzie and colleagues are now reformulating the drug to develop new ways to safely administer it.

"Although flubendazole faces important challenges with regard to safety, the potential benefits that could result relatively quickly from a safe, usable formulation make this a top priority for the filarial world today," he said.

With the new funding, Mackenzie and his team will continue to research the drug and test it in infection models. Next will come the standard safety testing needed to register a drug for human use, and after about two years, Mackenzie hopes, clinical trials will begin.

"We need to assess the safety profile of flubendazole in pre-clinical studies to further reformulate it and develop a safe, effective and field-adapted drug candidate," he said. "This drug is the only drug candidate on the horizon that has demonstrated positive results."

Mackenzie was awarded the funding as part of a larger $6 million grant given to DNDi, a Geneva-based nonprofit research-and-development organization. Timothy Geary from McGill University in Quebec, Canada, continues to work with Mackenzie on the project, which received $2 million in funding from the Gates Foundation in February 2010. The MSU-led team will include a number of global collaborators, including Carlos Lanusse in Argentina, Samuel Wanji in Cameroon and Rob Eversole at Western Michigan University.

Mackenzie has been studying filarial diseases for more than 30 years and has done extensive work in Tanzania and Ecuador. DNDi, which stands for Drugs for Neglected Diseases initiative, was established in 2003 with the help of seven major global health organizations to focus on neglected diseases affecting the world's poor. For more information, go to www.dndi.org.


'/>"/>

Contact: Jason Cody
codyja@msu.edu
517-432-0924
Michigan State University
Source:Eurekalert  

Related biology news :

1. Unnatural chemical allows Salk researchers to watch protein action in brain cells
2. UTMB-led researchers awarded $7.8 million for Gulf spill study
3. John Theurer Cancer Center BMT researchers highlight the importance of social support
4. Researchers characterize biomechanics of ovarian cells according to phenotype at stages of cancer
5. Researchers engineer functioning small intestine in laboratory experiments
6. Researchers can predict accurately the outcome of pregnancies threatening to miscarry
7. Researchers decipher protein structure of key molecule in DNA transcription system
8. Geneticist receives Excellence in Science Award from coalition of biomedical researchers
9. Researchers predict locations for deer vs. car collisions
10. UBC researchers invent new drug delivery device to treat diabetes-related vision loss
11. U of M researchers contribute to global plant database, expanding ecosystems research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers closing in on safe treatment for parasitic diseases  
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... around the world, is pleased to announce the 2nd annual Precision Medicine Virtual ... premier, online-only conference focused on the development and advancements in precision medicine. , ...
(Date:2/22/2017)... VIRGINIA (PRWEB) , ... February 22, 2017 , ... ... today that Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in the ... CDER’s Pilot Drug Evaluation Staff has joined the company as an Expert Consultant. ...
(Date:2/21/2017)... TORONTO , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ... financial and operational results for the three months ended December ... Toronto -based life sciences and diagnostics company that develops ... ... "We continue to build on the commercial milestones achieved in ...
(Date:2/21/2017)... ... 2017 , ... The medical potential of stem cells is both extensive and ... due to their differentiating characteristics. Stem cells are unique as the have the potential ... to become tissue or organic-specific cells with special functions. , Stem cell therapy ...
Breaking Biology Technology: